Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.8 USD | -6.35% | -24.94% | -7.45% |
May. 14 | Transcript : Curis, Inc. - Special Call | |
May. 14 | Curis, Inc. Announces Additional Data from Take Aim Leukemia Study | CI |
Financials (USD)
Sales 2024 * | 8.78M | Sales 2025 * | 8.8M | Capitalization | 74.27M |
---|---|---|---|---|---|
Net income 2024 * | -48M | Net income 2025 * | -53M | EV / Sales 2024 * | 8.46 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 8.44 x |
P/E ratio 2024 * |
-1.92
x | P/E ratio 2025 * |
-2.57
x | Employees | 49 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.82% |
Latest transcript on Curis, Inc.
1 day | -6.35% | ||
1 week | -28.53% | ||
Current month | -23.13% | ||
1 month | -22.72% | ||
3 months | +12.49% | ||
6 months | +99.66% | ||
Current year | -7.45% |
Managers | Title | Age | Since |
---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 57 | 16-03-28 |
Diantha Duvall
DFI | Director of Finance/CFO | 52 | 22-07-25 |
Chief Tech/Sci/R&D Officer | - | 22-01-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kenneth Kaitin
BRD | Director/Board Member | 71 | 03-10-31 |
Martyn Greenacre
CHM | Chairman | 82 | 00-02-13 |
James Dentzer
CEO | Chief Executive Officer | 57 | 16-03-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.01% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 11.8 | -6.35% | 27,005 |
24-05-16 | 12.6 | -3.08% | 23,923 |
24-05-15 | 13 | -17.14% | 84,969 |
24-05-14 | 15.69 | +0.19% | 28,116 |
24-05-13 | 15.66 | -0.38% | 23,347 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.45% | 74.27M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- CRIS Stock